ClinicalTrials.gg
Not yet recruitingNCT07625735Updated Oct 27, 2026

MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastrointestinal Cancers

An observational study in Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors and Lymph Node Metastasis, sponsored by Shanghai Zhongshan Hospital. Not yet recruiting. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Shanghai Zhongshan Hospital · Observational

How we know

Updated Oct 27, 2026Start date movedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,000
Ages
18 Years to 95 Years
Sex
All
01

Study summary

Lymph node metastasis (LNM) is a key factor influencing treatment decisions and prognosis in patients with gastric cancer. Lymphatic invasion (LI) is an important pathological predictor of LNM and a core component of the eCURA risk scoring system after endoscopic submucosal dissection (ESD) for early gastric cancer. However, whether LI has the same predictive value for LNM across different mismatch repair (MMR) statuses remains unclear. Compared with proficient mismatch repair (pMMR) gastric cancer, deficient mismatch repair (dMMR) gastric cancer has distinct molecular pathological features and an immune-enriched tumor microenvironment. In early gastric cancer, if LI is associated with a lower LNM risk in dMMR tumors than in pMMR tumors, existing LI-based eCURA risk assessment may overestimate LNM risk in patients with dMMR early gastric cancer and consequently affect decisions regarding additional surgery after ESD.

Therefore, this study aims to systematically evaluate the association between MMR status, LI, and LNM using multi-center cohorts of patients with GC who underwent upfront gastrectomy or additional gastrectomy following ESD, and to explore the potential clinical value of incorporating MMR status into eCURA-based risk stratification for early GC. Furthermore, an independent colorectal cancer surgical cohort will be included to investigate whether these associations are consistent across different gastrointestinal malignancies.

02

Conditions studied

  • Gastric / Gastroesophageal Junction Adenocarcinoma
  • Mismatch Repair Deficient or MSI-High Solid Tumors
  • Lymph Node Metastasis
  • Lymphatic Invasion
  • Gastrointestinal Cancer
03

In context

Turcot syndrome

60 studies on the registry are indexed under Turcot syndrome; 29 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 671 across 13 observational studies indexed under Turcot syndrome.

Browse Turcot syndrome studies →

Lead sponsor

Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This multicenter, retrospective observational cohort study will include patients with pathologically confirmed gastric or gastroesophageal junction adenocarcinoma or colorectal adenocarcinoma treated at Zhongshan Hospital, Fudan University, and five participating centers in China.

Patients treated between January 2018 and April 2026 will be retrospectively identified from electronic medical records, surgical records, and pathology databases. The study population comprises three cohorts:

  1. Gastric cancer upfront surgery cohort: Patients who underwent upfront radical gastrectomy.
  2. Gastric cancer ESD cohort: Patients who underwent ESD with available pathological information for eCURA risk assessment.
  3. Colorectal cancer surgery cohort: Patients who underwent upfront radical surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gastric cancer upfront surgery cohort

    • Patients who underwent radical surgery for gastric cancer.
    • Patients who did not receive chemotherapy, radiotherapy, immunotherapy, or other antitumor treatments that may affect the pathological assessment of the primary tumor or lymph node before surgery.
    • Patients with confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma after surgery, including Siewert type II and III tumors only.
    • Patients with definite pathological assessment of lymphatic invasion and regional lymph node status.
    • Patients with available and definite MMR status.
  2. Gastric cancer ESD cohort

    • Patients who underwent ESD for gastric cancer.
    • Patients with pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma after ESD, including Siewert type II and III tumors only.
    • Patients with complete post-ESD pathological information, including histological type, depth of invasion, tumor size, ulcerative findings, lymphatic invasion status, venous invasion status, horizontal margin status, and vertical margin status.
    • Patients with available and definite MMR status.
  3. Colorectal cancer upfront surgery cohort

    • Patients who underwent radical surgery for colorectal cancer.
    • Patients who did not receive neoadjuvant chemotherapy, radiotherapy, immunotherapy, or other anti-tumor treatments that may affect the pathological assessment of the primary tumor or lymph node metastasis before surgery.
    • Patients with pathologically confirmed colorectal adenocarcinoma.
    • Patients with definite pathological assessment of lymphatic invasion and regional lymph node status.
    • Patients with available and definite MMR status.

Exclusion criteria

Exclusion Criteria:

  1. Gastric cancer upfront surgery cohort

    • Patients with other pathological types, such as gastric squamous cell carcinoma or neuroendocrine carcinoma.
    • Patients who received treatment before surgery, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, or other systemic antitumor treatments.
    • Patients with missing postoperative pathological information, resulting in inability to determine lymphatic invasion or regional lymph node status.
    • Patients with missing or indeterminate MMR status.
    • Patients with concurrent that may interfere with the determination of the origin of lymph node metastasis.
  2. Gastric cancer ESD cohort

    • Patients with other pathological types, such as gastric squamous cell carcinoma or neuroendocrine carcinoma.
    • Patients with missing post-ESD pathological information that precludes eCURA classification, eCURA risk score calculation, or assessment of lymphatic invasion status.
    • Patients with missing or indeterminate MMR status.
  3. Colorectal cancer upfront surgery cohort

    • Patients with other pathological types, such as neuroendocrine carcinoma.
    • Patients who received neoadjuvant treatment before surgery, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, or other systemic anti-tumor treatments.
    • Patients with missing postoperative pathological information, resulting in inability to determine lymphatic invasion or regional lymph node metastasis status.
    • Patients with missing or indeterminate MMR status.
    • Patients with concurrent malignancies that may interfere with the determination of the origin of lymph node metastasis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • dMMR gastric cancer

    Patients with gastric cancer classified as deficient mismatch repair (dMMR) based on routine pathological testing.

    Other: Mismatch repair (MMR) status · Other: Lymphatic invasion status

  • pMMR gastric cancer

    Patients with gastric cancer classified as proficient mismatch repair (pMMR) based on routine pathological assessment.

    Other: Mismatch repair (MMR) status · Other: Lymphatic invasion status

  • dMMR colorectal cancer

    Patients with pathologically confirmed colorectal adenocarcinoma classified as deficient mismatch repair (dMMR) based on routine immunohistochemical assessment of MLH1, PMS2, MSH2, and MSH6.

    Other: Mismatch repair (MMR) status · Other: Lymphatic invasion status

  • pMMR colorectal cancer

    Patients with pathologically confirmed colorectal adenocarcinoma classified as proficient mismatch repair (pMMR) based on routine immunohistochemical assessment of MLH1, PMS2, MSH2, and MSH6.

    Other: Mismatch repair (MMR) status · Other: Lymphatic invasion status

Interventions

  • OtherMismatch repair (MMR) status

    Mismatch repair (MMR) status was assessed as part of routine pathological evaluation. Patients were classified as deficient mismatch repair (dMMR) or proficient mismatch repair (pMMR) according to immunohistochemical expression of MLH1, PMS2, MSH2, and MSH6.

  • OtherLymphatic invasion status

    Lymphatic invasion status was determined from routine pathological reports and classified as LI-positive or LI-negative.

06

What researchers measure

Primary outcomes

  1. Lymph Node Metastasis Rate Among LI-Positive Gastric Cancer Patients

    LI positivity is defined as lymphatic invasion explicitly documented in the pathological report or tumor emboli within lymphatic vessels confirmed by D2-40 immunohistochemistry. LNM is defined as regional lymph node metastasis confirmed by postoperative pathological examination. The LNM rate among LI-positive patients is calculated as the number of patients with LNM divided by the total number of LI-positive patients in the corresponding group.

    Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery

Secondary outcomes

  1. LI Positivity Rate According to MMR Status

    This outcome evaluates differences in LI positivity rate between patients with dMMR and pMMR gastric cancer. LI positivity rate is calculated as the number of LI-positive patients divided by the total number of patients in each MMR group.

    Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery

  2. Overall LNM Rate According to MMR Status

    This outcome evaluates differences in overall LNM rate between patients with dMMR and pMMR gastric cancer. Overall LNM rate is calculated as the number of patients with pathologically confirmed LNM divided by the total number of patients in each MMR group.

    Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery

  3. eCURA Risk Stratification and LI Contribution in the Gastric Cancer ESD Cohort

    This outcome evaluates differences in eCURA classification, eCURA risk score distribution, and the contribution of LI to the risk score between dMMR and pMMR patients in the gastric cancer ESD cohort. LI contribution is assessed based on its role in eCURA-C2 classification and/or its component score contribution within the eCURA risk scoring system.

    Time frame: At pathological assessment of the ESD specimen, approximately 14 days after ESD

  4. LNM Rate Among LI-Positive Patients in the cohort undergoing additional gastrectomy after ESD

    This outcome evaluates differences in LNM risk between LI-positive dMMR and pMMR patients with early gastric cancer who underwent additional surgery after ESD. LNM is defined as regional lymph node metastasis confirmed by pathological examination of the additional surgical specimen. LNM rate is calculated as the number of patients with LNM divided by the total number of LI-positive patients in each MMR group.

    Time frame: At postoperative pathological assessment, approximately 14 days after additional surgery

Other outcomes

  1. LNM Rate Among LI-Positive Colorectal Cancer Patients According to MMR Status

    This outcome compares the rate of pathologically confirmed LNM between LI-positive dMMR and pMMR colorectal cancer patients. LNM rate is calculated as the number of patients with LNM divided by the total number of LI-positive patients in each MMR group. Exploratory subgroup analyses will be performed according to pathological T stage.

    Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.

  2. LI Positivity Rate According to MMR Status in Colorectal Cancer

    This outcome compares the proportion of LI-positive patients between dMMR and pMMR colorectal cancer groups. LI positivity rate is calculated as the number of LI-positive patients divided by the total number of patients in each MMR group.

    Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.

  3. Overall LNM Rate According to MMR Status in Colorectal Cancer

    This outcome compares the overall rate of pathologically confirmed LNM between dMMR and pMMR colorectal cancer patients. LNM rate is calculated as the number of patients with LNM divided by the total number of patients in each MMR group.

    Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared due to patient privacy concerns and institutional data protection regulations. De-identified aggregate data may be made available from the corresponding author upon reasonable request and with appropriate institutional approval.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Jul 2026 → Nov 2026 and primary completion Nov 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
Jun 4, 2026
StartEst.
Nov 1, 2026was Jul 2026
Primary completionEst.
Jan 30, 2027was Nov 2026
CompletionEst.
Jul 31, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 1, 2026→Nov 1, 2026
Oct 27, 2026
Primary completion
Nov 30, 2026→Jan 30, 2027
Oct 27, 2026
Enrollment
3000→5000
Oct 27, 2026
Eligibility
4 inclusion criteria edited, 6 added; 2 exclusion criteria edited, 6 added
What changed in the criteria
Inclusion criteria
  • EditedUpfrontGastric cancer upfront surgery cohort
  • EditedPatients who underwent radical surgery for gastric cancer at Zhongshan Hospital, Fudan University.
  • EditedGastric cancer ESD cohort
  • EditedPatients who underwent ESD for gastric cancer at Zhongshan Hospital, Fudan University.
  • AddedColorectal cancer upfront surgery cohort
  • AddedPatients who underwent radical surgery for colorectal cancer.
  • AddedPatients who did not receive neoadjuvant chemotherapy, radiotherapy, immunotherapy, or other anti-tumor treatments that may affect the pathological assessment of the primary tumor or lymph node metastasis before surgery.
  • AddedPatients with pathologically confirmed colorectal adenocarcinoma.
  • AddedPatients with definite pathological assessment of lymphatic invasion and regional lymph node status.
  • AddedPatients with available and definite MMR status.
Exclusion criteria
  • EditedUpfrontGastric cancer upfront surgery cohort
  • EditedGastric cancer ESD cohort
  • AddedColorectal cancer upfront surgery cohort
  • AddedPatients with other pathological types, such as neuroendocrine carcinoma.
  • AddedPatients who received neoadjuvant treatment before surgery, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, or other systemic anti-tumor treatments.
  • AddedPatients with missing postoperative pathological information, resulting in inability to determine lymphatic invasion or regional lymph node metastasis status.
  • AddedPatients with missing or indeterminate MMR status.
  • AddedPatients with concurrent malignancies that may interfere with the determination of the origin of lymph node metastasis.
Oct 27, 2026
Interventions
Arms added: dMMR colorectal cancer·pMMR colorectal cancer
Oct 27, 2026
Secondary outcomes
3 added
What changed in the outcomes
  • Addedother outcomeLNM Rate Among LI-Positive Colorectal Cancer Patients According to MMR StatusTime frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.
  • Addedother outcomeLI Positivity Rate According to MMR Status in Colorectal CancerTime frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.
  • Addedother outcomeOverall LNM Rate According to MMR Status in Colorectal CancerTime frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.
Oct 27, 2026
Title
MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric CancerGastrointestinal Cancers
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Start date Jul 1, 2026→Nov 1, 2026
    Primary completion Nov 30, 2026→Jan 30, 2027
    Enrollment 3000→5000
    Eligibility 4 inclusion criteria edited, 6 added; 2 exclusion criteria edited, 6 added
    What changed in the criteria
    Inclusion criteria
    • EditedUpfrontGastric cancer upfront surgery cohort
    • EditedPatients who underwent radical surgery for gastric cancer at Zhongshan Hospital, Fudan University.
    • EditedGastric cancer ESD cohort
    • EditedPatients who underwent ESD for gastric cancer at Zhongshan Hospital, Fudan University.
    • AddedColorectal cancer upfront surgery cohort
    • AddedPatients who underwent radical surgery for colorectal cancer.
    • AddedPatients who did not receive neoadjuvant chemotherapy, radiotherapy, immunotherapy, or other anti-tumor treatments that may affect the pathological assessment of the primary tumor or lymph node metastasis before surgery.
    • AddedPatients with pathologically confirmed colorectal adenocarcinoma.
    • AddedPatients with definite pathological assessment of lymphatic invasion and regional lymph node status.
    • AddedPatients with available and definite MMR status.
    Exclusion criteria
    • EditedUpfrontGastric cancer upfront surgery cohort
    • EditedGastric cancer ESD cohort
    • AddedColorectal cancer upfront surgery cohort
    • AddedPatients with other pathological types, such as neuroendocrine carcinoma.
    • AddedPatients who received neoadjuvant treatment before surgery, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, or other systemic anti-tumor treatments.
    • AddedPatients with missing postoperative pathological information, resulting in inability to determine lymphatic invasion or regional lymph node metastasis status.
    • AddedPatients with missing or indeterminate MMR status.
    • AddedPatients with concurrent malignancies that may interfere with the determination of the origin of lymph node metastasis.
    Secondary outcomes 3 added
    What changed in the outcomes
    • Addedother outcomeLNM Rate Among LI-Positive Colorectal Cancer Patients According to MMR StatusTime frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.
    • Addedother outcomeLI Positivity Rate According to MMR Status in Colorectal CancerTime frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.
    • Addedother outcomeOverall LNM Rate According to MMR Status in Colorectal CancerTime frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.
    Interventions Arms added: dMMR colorectal cancer·pMMR colorectal cancer
    Title MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric CancerGastrointestinal Cancers
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07625735
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jan 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Zhaoqing Tang
Contact
tang.zhaoqing@zs-hospital.sh.cn
86-021-64041990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion